Skip to main content

Unoprostone ophthalmic Pregnancy and Breastfeeding Warnings

Brand names: Rescula

Unoprostone ophthalmic Pregnancy Warnings

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

Animal studies have shown an increase in the incidence of miscarriages, an increase in the incidence of premature delivery, a decrease in live birth index, and a decrease in weight at birth. There are no adequate and well-controlled studies in pregnant women.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Unoprostone ophthalmic Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

See references

See also

References for pregnancy information

  1. (2001) "Product Information. Rescula (unoprostone ophthalmic)." Ciba Vision Ophthalmics

References for breastfeeding information

  1. (2001) "Product Information. Rescula (unoprostone ophthalmic)." Ciba Vision Ophthalmics

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer